NADAC acquisition cost data for INVOKAMET 150-500 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
| 50458054260 | $9.03 | 2022-07-20 | Rx |
Generic: Canagliflozin/Metformin HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $40.6M | 51,911 | 12,529 | $8.28 |
| 2020 | $41.6M | 47,669 | 10,025 | $8.63 |
| 2021 | $30.0M | 32,143 | 7,591 | $9.02 |
| 2022 | $27.5M | 26,316 | 5,871 | $9.70 |
| 2023 | $22.2M | 19,428 | 4,565 | $10.28 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $2.7M | 2,449 | 562 |
| Texas | $1.9M | 1,550 | 397 |
| Florida | $1.6M | 1,420 | 353 |
| New York | $1.6M | 1,360 | 331 |
| North Carolina | $1.3M | 1,180 | 243 |
| Pennsylvania | $1.3M | 1,221 | 260 |
| New Jersey | $804.9K | 645 | 160 |
| Ohio | $796.4K | 675 | 161 |
| Georgia | $794.4K | 653 | 164 |
| Michigan | $631.7K | 521 | 129 |
| Tennessee | $574.5K | 475 | 117 |
| Illinois | $573.9K | 484 | 125 |
| Puerto Rico | $523.6K | 715 | 220 |
| Alabama | $486.6K | 464 | 118 |
| Kentucky | $470.8K | 378 | 81 |
| Indiana | $465.9K | 365 | 91 |
| Kansas | $458.9K | 453 | 74 |
| South Carolina | $451.3K | 409 | 106 |
| Missouri | $411.0K | 362 | 81 |
| Louisiana | $315.9K | 294 | 67 |
| Mississippi | $315.2K | 295 | 63 |
| Arizona | $307.8K | 223 | 61 |
| Virginia | $290.4K | 216 | 62 |
| Colorado | $287.5K | 263 | 68 |
| Minnesota | $237.6K | 189 | 41 |
| Nevada | $227.7K | 151 | 48 |
| Maryland | $198.0K | 130 | 39 |
| Oklahoma | $188.7K | 174 | 44 |
| Massachusetts | $181.3K | 154 | 39 |
| Connecticut | $179.1K | 153 | 39 |
| Arkansas | $157.5K | 149 | 32 |
| Wisconsin | $144.1K | 124 | 29 |
| South Dakota | $143.7K | 150 | 23 |
| Iowa | $135.9K | 124 | 27 |
| Washington | $119.2K | 93 | 26 |
| Utah | $119.1K | 96 | 26 |
| Nebraska | $116.3K | 126 | 20 |
| Hawaii | $110.3K | 67 | 20 |
| West Virginia | $95.3K | 67 | 21 |
| Delaware | $83.9K | 63 | 17 |
| New Mexico | $62.1K | 49 | 17 |
| Montana | $59.5K | 59 | N/A |
| District of Columbia | $52.4K | 47 | 12 |
| Oregon | $49.7K | 34 | N/A |
| North Dakota | $44.6K | 53 | 12 |
| Maine | $33.9K | 21 | N/A |
| New Hampshire | $24.6K | 15 | N/A |
| Idaho | $21.2K | 24 | N/A |
| Rhode Island | $17.5K | 21 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.